Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth

Lu Xue, Nita Jane Maihle, Xiaolin Yu, Shou Ching Tang, HongYan Liu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

HER2 overexpression is identified on 20-30% breast cancer and other cancers at different levels. Although HER2 targeted monoclonal antibody combined with chemical drugs has shown improved outcomes in HER2 expressing patients, drug resistance and toxicity have limited their efficacy. To overcome drug resistance, cotargeting multiple HER receptors was proven to be effective. EGFR/HER2 dimerization can active PI3K/AKT pathway, and resistance to HER2-targeted drugs is associated with upregulation of EGFR. Here, we developed a novel HER2/EGFR targeted nucleic acid therapeutic to address current drug limits. The new therapeutic is constructed by fusing HER2 aptamer-EGFR siRNA sense strand with HER2 aptamer-EGFR siRNA antisense strand into one molecule: a bivalent HER2 aptamer-EGFR siRNA aptamer chimera (HEH). In breast cancer cell lines, HEH can be selectively taken up into HER2 expressing cells and successfully silence EGFR gene and down regulate HER2 expression. In breast cancer xenograft models, HEH is capable of triggering cell apoptosis, decreasing HER2 and EGFR expression, and suppressing tumor growth. The therapeutic efficacy of HEH is superior to HER2 aptamer only, which suggests that HEH has synergistic effect by targeting HER2 and EGFR. This study demonstrated that HEH has great potential as a new HER2 targeted drug to address toxicity and resistance of current drugs and may provide a cure for many HER2 positive cancers.

Original languageEnglish (US)
Pages (from-to)4801-4813
Number of pages13
JournalMolecular Pharmaceutics
Volume15
Issue number11
DOIs
StatePublished - Nov 5 2018

Fingerprint

Small Interfering RNA
Breast Neoplasms
Growth
Drug Resistance
Pharmaceutical Preparations
Neoplasms
erbB-1 Genes
Dimerization
Multiple Drug Resistance
Drug-Related Side Effects and Adverse Reactions
Phosphatidylinositol 3-Kinases
Heterografts
Nucleic Acids
Up-Regulation
Therapeutics
Down-Regulation
Monoclonal Antibodies
Apoptosis
Cell Line

Keywords

  • HER2
  • aptamer
  • bivalent
  • siRNA
  • siRNA delivery
  • synergistic treatment
  • targeted therapeutic

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth. / Xue, Lu; Maihle, Nita Jane; Yu, Xiaolin; Tang, Shou Ching; Liu, HongYan.

In: Molecular Pharmaceutics, Vol. 15, No. 11, 05.11.2018, p. 4801-4813.

Research output: Contribution to journalArticle

Xue, Lu ; Maihle, Nita Jane ; Yu, Xiaolin ; Tang, Shou Ching ; Liu, HongYan. / Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth. In: Molecular Pharmaceutics. 2018 ; Vol. 15, No. 11. pp. 4801-4813.
@article{8e668a24ddf14e20b654e79e3a4f8107,
title = "Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth",
abstract = "HER2 overexpression is identified on 20-30{\%} breast cancer and other cancers at different levels. Although HER2 targeted monoclonal antibody combined with chemical drugs has shown improved outcomes in HER2 expressing patients, drug resistance and toxicity have limited their efficacy. To overcome drug resistance, cotargeting multiple HER receptors was proven to be effective. EGFR/HER2 dimerization can active PI3K/AKT pathway, and resistance to HER2-targeted drugs is associated with upregulation of EGFR. Here, we developed a novel HER2/EGFR targeted nucleic acid therapeutic to address current drug limits. The new therapeutic is constructed by fusing HER2 aptamer-EGFR siRNA sense strand with HER2 aptamer-EGFR siRNA antisense strand into one molecule: a bivalent HER2 aptamer-EGFR siRNA aptamer chimera (HEH). In breast cancer cell lines, HEH can be selectively taken up into HER2 expressing cells and successfully silence EGFR gene and down regulate HER2 expression. In breast cancer xenograft models, HEH is capable of triggering cell apoptosis, decreasing HER2 and EGFR expression, and suppressing tumor growth. The therapeutic efficacy of HEH is superior to HER2 aptamer only, which suggests that HEH has synergistic effect by targeting HER2 and EGFR. This study demonstrated that HEH has great potential as a new HER2 targeted drug to address toxicity and resistance of current drugs and may provide a cure for many HER2 positive cancers.",
keywords = "HER2, aptamer, bivalent, siRNA, siRNA delivery, synergistic treatment, targeted therapeutic",
author = "Lu Xue and Maihle, {Nita Jane} and Xiaolin Yu and Tang, {Shou Ching} and HongYan Liu",
year = "2018",
month = "11",
day = "5",
doi = "10.1021/acs.molpharmaceut.8b00388",
language = "English (US)",
volume = "15",
pages = "4801--4813",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth

AU - Xue, Lu

AU - Maihle, Nita Jane

AU - Yu, Xiaolin

AU - Tang, Shou Ching

AU - Liu, HongYan

PY - 2018/11/5

Y1 - 2018/11/5

N2 - HER2 overexpression is identified on 20-30% breast cancer and other cancers at different levels. Although HER2 targeted monoclonal antibody combined with chemical drugs has shown improved outcomes in HER2 expressing patients, drug resistance and toxicity have limited their efficacy. To overcome drug resistance, cotargeting multiple HER receptors was proven to be effective. EGFR/HER2 dimerization can active PI3K/AKT pathway, and resistance to HER2-targeted drugs is associated with upregulation of EGFR. Here, we developed a novel HER2/EGFR targeted nucleic acid therapeutic to address current drug limits. The new therapeutic is constructed by fusing HER2 aptamer-EGFR siRNA sense strand with HER2 aptamer-EGFR siRNA antisense strand into one molecule: a bivalent HER2 aptamer-EGFR siRNA aptamer chimera (HEH). In breast cancer cell lines, HEH can be selectively taken up into HER2 expressing cells and successfully silence EGFR gene and down regulate HER2 expression. In breast cancer xenograft models, HEH is capable of triggering cell apoptosis, decreasing HER2 and EGFR expression, and suppressing tumor growth. The therapeutic efficacy of HEH is superior to HER2 aptamer only, which suggests that HEH has synergistic effect by targeting HER2 and EGFR. This study demonstrated that HEH has great potential as a new HER2 targeted drug to address toxicity and resistance of current drugs and may provide a cure for many HER2 positive cancers.

AB - HER2 overexpression is identified on 20-30% breast cancer and other cancers at different levels. Although HER2 targeted monoclonal antibody combined with chemical drugs has shown improved outcomes in HER2 expressing patients, drug resistance and toxicity have limited their efficacy. To overcome drug resistance, cotargeting multiple HER receptors was proven to be effective. EGFR/HER2 dimerization can active PI3K/AKT pathway, and resistance to HER2-targeted drugs is associated with upregulation of EGFR. Here, we developed a novel HER2/EGFR targeted nucleic acid therapeutic to address current drug limits. The new therapeutic is constructed by fusing HER2 aptamer-EGFR siRNA sense strand with HER2 aptamer-EGFR siRNA antisense strand into one molecule: a bivalent HER2 aptamer-EGFR siRNA aptamer chimera (HEH). In breast cancer cell lines, HEH can be selectively taken up into HER2 expressing cells and successfully silence EGFR gene and down regulate HER2 expression. In breast cancer xenograft models, HEH is capable of triggering cell apoptosis, decreasing HER2 and EGFR expression, and suppressing tumor growth. The therapeutic efficacy of HEH is superior to HER2 aptamer only, which suggests that HEH has synergistic effect by targeting HER2 and EGFR. This study demonstrated that HEH has great potential as a new HER2 targeted drug to address toxicity and resistance of current drugs and may provide a cure for many HER2 positive cancers.

KW - HER2

KW - aptamer

KW - bivalent

KW - siRNA

KW - siRNA delivery

KW - synergistic treatment

KW - targeted therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85054353439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054353439&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.8b00388

DO - 10.1021/acs.molpharmaceut.8b00388

M3 - Article

C2 - 30222359

AN - SCOPUS:85054353439

VL - 15

SP - 4801

EP - 4813

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 11

ER -